The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

Die EMA hat gestern nach einer Neubewertung eine beschränkte Zulassung für das umstrittene Medikament erlassen. Noch sind ...

Im Sommer sprach sich die EMA noch gegen eine Zulassung des Amyloid-Antikörpers Lecanemab im frühen Alzheimer-Stadium aus.

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...

Erstmals steht in der EU eine Therapie gegen Alzheimer vor der Zulassung. Sie ist allerdings nur für einen kleinen Teil der ...

Eisai (ESAIY) and Biogen (BIIB) announced that a positive opinion has been received from the Committee for Medicinal Products for Human Use of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Future of Healthcategory Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest July 30, 2024 Businesscategory Shares of Japan's Eisai tumble after EU rejects ...

This research was funded by Eisai GmbH, Germany. Eisai GmbH was informed throughout the process of data collection and analyses, and contributed to the research through critical review of results ...

Die Liquidation einer GmbH ist ein detaillierter und rechtlich anspruchsvoller Prozess. Es ist essenziell, die gesetzlichen Vorschriften und Fristen einzuhalten, um rechtliche und finanzielle Risi ...

According to a New York Times report this week, Eisai and Eli Lilly, in the clinical trials for their respective Alzheimer’s drugs Leqembi and Kisunla, genetically tested participants to ...

For the drugmaker Eisai, the trial was a shot at a windfall — potentially billions of dollars — for defanging a disease that had confounded researchers for more than a century. To assess the ...